A method for preparing a single-dose plasma albumin product

By replacing the low-temperature ethanol method with a full chromatography process, and using a five-step chromatography process and specific packing materials to prepare plasma albumin, the problems of high safety risks, low product quality, and poor production flexibility have been solved, and high-purity, high-yield, and flexible single-dose preparation has been achieved.

CN123106879APending Publication Date: 2026-11-17HUALAN BIOLOGICAL ENG CHONGQING
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611501985.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-24
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The existing low-temperature ethanol method for preparing human serum albumin has problems such as high safety risks, low product quality and yield, difficulty in linear scale-up, and poor production flexibility.

Method used

Plasma albumin is prepared using a full chromatography process, which involves five steps: first anion exchange chromatography, second anion exchange chromatography, cation exchange chromatography, third anion exchange chromatography, and hydrophobic chromatography. Protein separation is achieved by using flow-through modes under different pH and conductivity conditions, avoiding the use of ethanol and strong acid-base elution, and using specific packing materials such as sulfopropyl, butyl, and phenyl.

Benefits of technology

It achieves improved safety, product purity of over 90%, increased yield, suitability for single-serving processing, avoids damage to albumin structure caused by ethanol precipitation, has clear parameter control, is suitable for different production scales, and reduces production costs and facility investment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106879A_ABST
    Figure CN123106879A_ABST
Patent Text Reader

Abstract

This invention relates to the field of blood product manufacturing technology, specifically to a method for preparing a single-dose plasma albumin product. The method involves centrifuging or filtering the plasma to obtain the liquid phase; this liquid phase is then subjected to a series of chromatography steps: a first anion exchange chromatography, a second anion exchange chromatography, a cation exchange chromatography, a third anion exchange chromatography, and a hydrophobic chromatography, to obtain the plasma albumin product. This technical solution achieves continuous extraction and purification of single-dose plasma albumin through multiple ion exchange chromatography experiments. Furthermore, the all-chromatographic approach avoids the use of low-temperature ethanol methods, improving production safety and reducing investment costs for explosion-proof facilities. This technical solution addresses the technical problems of high safety risks, low product quality and yield, difficulty in linear scale-up, and poor production flexibility associated with existing low-temperature ethanol methods for preparing human serum albumin, and has promising prospects for application and promotion.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of blood product manufacturing technology, specifically to a method for preparing a single-dose plasma albumin product. Background Technology

[0002] Human serum albumin is an important blood product extracted from the plasma of healthy individuals. It has a variety of key physiological functions, including maintaining the colloidal osmotic pressure of human plasma, transporting drugs and various small molecules, scavenging free radicals in the body, inhibiting the production of oxygen free radicals by polymorphonuclear cells, and having a certain anticoagulant effect. It is now widely used in clinical practice and plays an irreplaceable role in the treatment of conditions such as blood loss trauma, burn shock, hypoproteinemia, and neonatal hyperbilirubinemia.

[0003] Currently, the industrial production of human serum albumin still mainly relies on the low-temperature ethanol method (Cohn method) and its improved processes. Since its introduction, this method has become the mainstream technical route for plasma protein separation worldwide, and most domestic production enterprises have adopted this process to achieve large-scale production. However, the low-temperature ethanol method has many inherent drawbacks, severely restricting the improvement of product quality, production safety, and production flexibility. Specific technical problems are as follows: First, the low-temperature ethanol method requires ethanol as a precipitant, and ethanol is a flammable and explosive substance, posing extremely high production safety risks and requiring dedicated explosion-proof workshops and supporting safety facilities, significantly increasing production investment costs. Second, this process requires multiple cycles of precipitation and redissolution to separate albumin from other proteins. This process not only damages the molecular structure of albumin and reduces its biological activity, leading to low product yield, but also affects the purity of the final product due to low separation resolution. Furthermore, high-concentration ethanol itself can also damage the albumin structure, further affecting product quality. Third, the larger the production scale of the low-temperature ethanol method, the more difficult it is to control parameters and the more difficult the production process becomes to manage. Moreover, the process is difficult to scale up linearly, and when converting a small-scale process to large-scale production, problems such as parameter fluctuations and large batch-to-batch differences easily occur, making it unable to flexibly adapt to the needs of different production scales.

[0004] Chromatography, as a highly efficient method for protein separation and purification, has become one of the most important purification technologies in downstream biological processing. It can be used for primary, intermediate, and fine separation, offering advantages such as high separation accuracy, simple equipment, and convenient operation. Ion exchange chromatography, in particular, features high resolution and high protein binding capacity, while gel chromatography offers advantages such as ease of operation, reusable separation media, good separation effect, high repeatability, and high sample recovery. How to utilize these chromatographic techniques to form a complete chromatographic process, thereby replacing the precipitation step in the low-temperature ethanol method, is a problem that urgently needs to be solved. Developing a complete chromatographic process could fundamentally avoid the safety risks associated with ethanol use, while also preventing damage to the albumin structure and activity caused by the precipitation-redissolution process, thus helping to improve product purity and yield.

[0005] In summary, the existing low-temperature ethanol method for preparing human serum albumin has technical problems such as high safety risks, low product quality and yield, difficulty in linear scale-up, and poor production flexibility. Therefore, developing a new method for preparing plasma albumin products to overcome the above defects has important practical significance and application value. Summary of the Invention

[0006] The present invention aims to provide a method for preparing single-dose plasma albumin products, in order to solve the technical problems of high safety risks, low product quality and yield, difficulty in linear scale-up, and poor production flexibility in the preparation of human serum albumin by the low-temperature ethanol method in the prior art.

[0007] To achieve the above objectives, the present invention adopts the following technical solution: A method for preparing a single-dose plasma albumin product involves centrifuging or filtering the plasma to obtain the liquid phase; sequentially subjecting the liquid phase to a first anion exchange chromatography, a second anion exchange chromatography, a cation exchange chromatography, a third anion exchange chromatography, and a hydrophobic chromatography to obtain the plasma albumin product.

[0008] Furthermore, in the first anion exchange chromatography, the pH of the liquid phase is adjusted to 6.8–7.7 and the conductivity to 10.0–12.0 mS / cm to obtain the first chromatographic solution; the first chromatographic solution is loaded into the anion exchange chromatography column, and the flow-through is collected to obtain the first chromatographic flow-through.

[0009] Furthermore, in the second anion exchange chromatography, the pH of the first chromatography flow-through solution was adjusted to 6.0–7.2 and the conductivity to 4.0–9.0 mS / cm to obtain the second chromatography solution; the second chromatography solution was loaded into the anion exchange chromatography column, and the flow-through solution was collected to obtain the second chromatography flow-through solution.

[0010] Furthermore, in cation exchange chromatography, the pH of the second chromatography flow-through solution is adjusted to 5.2–5.4 and the conductivity to 0.5–2.0 mS / cm to obtain the cation exchange chromatography solution; the cation exchange chromatography solution is loaded onto the cation exchange chromatography column, and the flow-through solution is collected to obtain the cation exchange chromatography flow-through solution.

[0011] Furthermore, after the third anion exchange chromatography, the pH of the cation exchange chromatography flow-through solution was adjusted to 6.5–7.6 and the conductivity to 1.5–2.5 mS / cm to obtain the third chromatography solution; the third chromatography solution was loaded into the anion exchange chromatography column, and the flow-through solution was collected to obtain the third chromatography flow-through solution.

[0012] Furthermore, in hydrophobic exchange chromatography, the pH of the third chromatography flow-through solution is adjusted to 7.4–7.6 and the conductivity to 12–82 mS / cm to obtain the hydrophobic chromatography solution; the hydrophobic chromatography solution is loaded into the hydrophobic chromatography column, and the flow-through solution is collected to obtain the hydrophobic chromatography flow-through solution.

[0013] Furthermore, after ultrafiltration, dialysis and concentration, the hydrophobic chromatography flow-through solution is mixed with sodium octanoate and sodium chloride to obtain an intermediate product with a protein content >100 g / L, a sodium octanoate content of 0.120–0.200 mmol / g protein, a sodium chloride content of 50–150 mmol / L, and a pH value of 6.2–7.6. After pasteurization and filtration, the intermediate products are used to obtain albumin products.

[0014] Furthermore, the ligands used in cation exchange chromatography are sulfopropyl groups. For example, Unigel 80sp (Suzhou Nanomicro).

[0015] Furthermore, the ligands of the packing material used in the first and second anion exchange chromatography are trimethylaminoethyl. For example: Fractogel EMD TMAE(M) (Merck).

[0016] The packing material used in the third anion exchange chromatography has a trimethyl quaternary ammonium ligand. For example, GPQ-60 (Suzhou Bojin).

[0017] Furthermore, the ligand of the packing material used in hydrophobic chromatography is butyl or phenyl, and the matrix of the packing material is a cross-linked agarose gel skeleton or polyacrylate, specifically Diamond Butyl, Capto phenyl, or Capto Butyl.

[0018] This technical solution also provides a method for preparing a single-dose plasma albumin product.

[0019] The technical principle of this technical solution is as follows: This technical solution provides a full-chromatographic process route for albumin in plasma, which is a separation and purification path consisting of an ordered combination of ion exchange chromatography and hydrophobic chromatography. This invention employs a flow-through mode for ion exchange chromatography: under suitable pH and conductivity conditions, the target albumin flows directly through without binding to the chromatographic medium, while impurity proteins are adsorbed and removed by the medium. This mode avoids the impact of strong acid-base elution solutions on the conformation of albumin during traditional adsorption and elution processes, thus helping to maintain the product's native activity. This invention designs a five-step chromatographic preparation process: The first anion exchange chromatography (material to be chromatographically analyzed: pH 6.8–7.7, conductivity 10.0–12.0 mS / cm) serves as a crude purification step. At a high conductivity, most albumin flows directly through, while impurities are efficiently removed, thus achieving clarification and preliminary impurity removal.

[0020] The second anion exchange chromatography (material to be chromatographically analyzed: pH 6.0–7.2, conductivity 4.0–9.0 mS / cm) was performed under lower pH and conductivity conditions. At this time, albumin still remained in a flow-through state, further separating impurities and further improving albumin purity.

[0021] Cation exchange chromatography (material to be chromatographically analyzed: pH 5.2–5.4, conductivity 0.5–2.0 mS / cm) is the key purification step in this invention. Within this extremely narrow pH and conductivity window, impurities such as IgG are strongly adsorbed by the cation exchange medium, while albumin flows smoothly through at this pH. Through extensive experiments, the inventors have discovered that this step has very stringent requirements regarding pH and conductivity. A pH deviation exceeding 5.45 or a conductivity deviation exceeding 2.0 mS / cm will result in a sharp decrease in albumin purity.

[0022] The third anion exchange chromatography (material to be chromatographically analyzed: pH 6.5–7.6, conductivity 1.5–2.5 mS / cm) is a fine purification step, which is run at a lower ionic strength. At this time, albumin flows through while trace impurities are efficiently removed, providing a highly clean feed for subsequent hydrophobic chromatography.

[0023] Hydrophobic chromatography (material to be chromatographically analyzed: pH 7.4–7.6, conductivity 12–82 mS / cm) utilizes the difference in surface hydrophobicity between albumin and residual trace hydrophobic impurities. Under high-salt conditions, the hydrophobic impurities bind to the medium, while the albumin flows through and is collected. This step effectively removes hydrophobic impurities and polymers that are difficult to separate by ion exchange chromatography, further ensuring the purity of the final product.

[0024] Compared with existing technologies, this technical solution has the following advantages: This invention employs a full chromatography process, completely replacing the ethanol precipitation step in the low-temperature ethanol method. This fundamentally avoids the use of flammable and explosive ethanol, eliminating the safety hazards of combustion and explosion during production. It eliminates the need for explosion-proof workshops and dedicated safety facilities, significantly reducing investment and operating costs and improving production safety. The plasma albumin products obtained using this method, after pasteurization and sterile filtration, meet all quality indicators of the Chinese Pharmacopoeia and clinical use standards, demonstrating broad application prospects.

[0025] This invention avoids the damage to the tertiary structure of albumin caused by ethanol precipitation and the precipitation-redissolution cycle. In particular, albumin flows through each chromatography column in a continuous flow-through mode, without being subjected to elution shocks from strong acids, strong alkalis, or high-concentration salts, thus preserving the native conformation and biological activity of albumin to the greatest extent. Simultaneously, through five-step chromatography separation, the final product purity can reach over 90%, and the yield is significantly improved compared to the low-temperature ethanol method, breaking through the yield bottleneck of traditional processes.

[0026] The chromatography process of this invention is based on predictable physicochemical interactions between the medium and the target analyte. Parameter control is precise, and the process is easily standardized. Linear scale-up from laboratory to production scale can be achieved by proportionally scaling the column diameter and column bed height, resulting in good batch-to-batch consistency. More importantly, this invention is particularly suitable for the independent processing of single-sample plasma, breaking the limitations of traditional large-volume production. It enables single-collection, single-processing, effectively avoiding the risk of cross-mixing of plasma from different sources and improving product traceability and personalized supply capabilities. Attached Figure Description

[0027] Figure 1 This is a flowchart of the preparation process of the plasma albumin product in Example 1.

[0028] Figure 2 This is a schematic diagram of the overall equipment for preparing plasma albumin products in Example 1.

[0029] Figure 3 This is a schematic diagram of the chromatography column connection of the equipment used to prepare the plasma albumin product in Example 1.

[0030] Figure 4 This is a schematic diagram of the chromatography column connection of the equipment used to prepare the plasma albumin product in Example 2.

[0031] Figure 5 This is a front view of the plasma separation kit of Example 2.

[0032] Figure 6 This is a front view of the cold precipitation separation unit in Example 2.

[0033] Figure 7 This is a front view of the improved plasma separation kit of Example 2. Detailed Implementation

[0034] The present invention will be further described in detail below with reference to embodiments, but the implementation of the present invention is not limited thereto. Unless otherwise specified, the technical means used in the following embodiments and experimental examples are conventional means well known to those skilled in the art, and the materials and reagents used can all be obtained commercially.

[0035] The specific reference numerals in the attached figures are as follows: First anion exchange chromatography column 1, Second anion exchange chromatography column 2, Cation exchange chromatography column 3, Third anion exchange chromatography column 4, Hydrophobic chromatography column 5, Cold precipitation separation unit 6, Pump 7, Valve 8, Computer 9, Chromatography unit chassis 10, Fixed surface 11, Grille 12, First pipeline 13, Second pipeline 14, Third pipeline 15, Fourth pipeline 16, Fifth pipeline 17, Sixth pipeline 18, Seventh pipeline 19, Eighth pipeline 20, Ninth pipeline 21, Tenth pipeline 22, Eleventh pipeline 23, Twelfth pipeline 24, Thirteenth pipeline 25, Fourteenth pipeline 26, Fifteenth pipeline 27, Sixteenth pipeline 28, First container 29, Top cover 30, Stirring assembly 31, Motor 32, Filter membrane 33, Pressure regulating pipe 34, Second container 35, Outlet pipe 36, Cold box 37, Pressurized filter membrane 38, Third container 39.

[0036] Example 1 (I) Preparation process of plasma albumin This technical solution is an improvement based on the applicant's prior patented technologies, namely: "CN116236820A A Continuous Production System for Single-Unit Plasma IgG Products" and "CN116574175A A Single-Unit Plasma IgG Product and its Preparation Method". The original solution pertains to the preparation process and equipment for single-unit plasma IgG from frozen raw plasma. This process and equipment are now modified for application in the preparation process of single-unit plasma albumin. The preparation flow for plasma albumin is as follows (see flowchart). Figure 1 ): (1) Raw plasma processing: After the raw plasma is discharged from the warehouse, the surface of the plasma bag is disinfected with 70% to 75% ethanol solution. The plasma bag is then broken open and thawed at a controlled temperature of 0 to 4°C. After thawing, the plasma is centrifuged at a speed of 10,000 rpm or higher and the supernatant is collected. The plasma used in this step (raw plasma) is the human plasma referred to in the Chinese Pharmacopoeia: Human plasma for blood product production is plasma from healthy individuals collected by apheresis for the production of plasma protein products. It is the supernatant after centrifugation to remove cells from the blood and contains proteins, inorganic salts, and water, but does not contain blood cells.

[0037] (2) First Anion Exchange Chromatography: Adjust the pH of the plasma supernatant after centrifugation to 6.8–7.7 and the conductivity to 10.0–12.0 mS / cm. Filter the supernatant using a 0.22 μm filter cartridge (this step can be omitted in a continuous production system) to obtain the first chromatography solution. The preparation of the first chromatography solution can be done without using a 0.22 μm filter cartridge. Through extensive experimental research, the inventors discovered that adjusting the pH and conductivity to the above ranges in this step prevents protein precipitation. Especially in continuous production systems, filtration with a 0.22 μm filter cartridge can be omitted to accelerate production and avoid disruption to production continuity due to protein precipitation. Perform a first anion exchange chromatography experiment on the first chromatography solution to adsorb IgM and coagulation factors. Collect the flow-through containing albumin (the first chromatography flow-through) for the next chromatography step.

[0038] The anion exchange chromatography packing material used in this step is a strong anion exchange chromatography packing material, such as a strong anion exchange chromatography packing material with trimethylaminoethyl (TMAE) as the functional group.

[0039] (3) Second anion exchange chromatography: Adjust the conductivity of the first chromatography flow-through to 6.0–7.2 mS / cm and the pH to 4.0–9.0. After filtration with a 0.22 μm filter cartridge (adjusting the pH and conductivity to the above range will prevent protein precipitation and can be omitted in continuous production systems), obtain the second chromatography solution. Perform a second anion exchange chromatography on the second chromatography solution to remove trace amounts of impurities and protein. Collect the flow-through containing albumin (second chromatography flow-through) for the next chromatography step.

[0040] The anion exchange chromatography packing material used in this step is a strong anion exchange chromatography packing material, such as a strong anion exchange chromatography packing material with trimethylaminoethyl (TMAE) as the functional group.

[0041] (4) Cation exchange chromatography: Adjust the pH of the second chromatography flow-through to 5.2–5.4 and the conductivity to 0.5–2.0 mS / cm (preferably 2.0 mS / cm). Filter the solution using a 0.22 μm filter cartridge (adjusting the pH and conductivity to the above range will prevent protein precipitation and can be omitted in continuous production systems) to obtain the cation exchange chromatography solution. Load the cation exchange chromatography solution onto a cation exchange chromatography column to adsorb IgG and flow through other non-IgG proteins (including the target protein of this protocol—albumin). Collect the flow-through containing albumin (cation exchange chromatography flow-through) for further purification.

[0042] The cation exchange chromatography packing material used in this step is a strong cation exchange chromatography packing material, such as a strong cation exchange chromatography packing material with sulfopropyl (SP) as the functional group.

[0043] The aforementioned steps (1)-(4) are basically the same as those in the applicant's prior patent, which are general procedures for obtaining plasma IgG and albumin. In step (4), plasma IgG and albumin are separated by a chromatography step, and the subsequent operation steps are specific to albumin.

[0044] (5) Third anion exchange chromatography: Adjust the conductivity of the previous cation exchange chromatography flow-through to 1.5–2.5 mS / cm and the pH to 6.5–7.6, and filter using a 0.22 μm filter cartridge (adjusting the pH and conductivity to the above range will prevent protein precipitation; the filtration step can be omitted in a continuous production system) to obtain the third chromatography solution. Load the third chromatography solution onto anion exchange chromatography column to remove trace amounts of impurities and collect the flow-through to obtain the third chromatography flow-through.

[0045] The anion exchange chromatography packing material used in this step is a strong anion exchange chromatography packing material, such as a strong anion exchange chromatography packing material with quaternary ammonium (Q) functional groups. More specifically, a packing material with trimethylaminepropyl functional groups can be selected.

[0046] (6) Hydrophobic chromatography: Collect the flow-through solution from the third chromatography step, adjust the conductivity to 12–82 mS / cm and the pH to 7.4–7.6, and filter it using a 0.22 μm filter cartridge (adjusting the pH and conductivity to the above range will prevent protein precipitation; the filtration step can be omitted in a continuous production system) to obtain the hydrophobic chromatography solution. Load the hydrophobic chromatography solution onto the hydrophobic chromatography column to remove trace amounts of impurities and collect the flow-through solution to obtain the hydrophobic chromatography flow-through solution.

[0047] The hydrophobic chromatography packing material used in this step is phenyl or butyl hydrophobic chromatography packing material, such as DiamondButyl, Captophenyl, or CaptoButyl.

[0048] (7) Subsequent processing steps: Collect the hydrophobic chromatography flow-through, perform ultrafiltration using a 10 kDa ultrafiltration membrane, dialyze 8 times with physiological saline, dialyze 5 times with injection water, and concentrate to a protein content >100 g / L to prepare a product with sodium caprylate 0.120–0.200 mmol / g protein, sodium chloride content 50–150 mmol / L, and pH value 6.2–7.6.

[0049] The albumin-containing products were pasteurized at 60℃±0.5℃ for 10 hours. After filtration through a 0.45±0.22μm filter cartridge, they were sterilized and packaged.

[0050] Albumin content was determined using a Beckman Coulter specific protein analysis system, total protein content was determined using an Yilanbei fully automated biochemical analyzer, and molecular size distribution was determined using liquid chromatography. Albumin purity was calculated as the ratio of sample albumin content to total protein content; albumin yield was calculated based on the ratio of albumin content to unfiltered albumin content at different experimental steps, yielding albumin yields for different steps.

[0051] This process can be used to analyze at least one plasma sample, and the maximum scale-up is theoretically unlimited, depending on the size of the chromatography column.

[0052] (II) Plasma albumin preparation system The system can be divided into two types: a stepwise production system and a continuous production system. The stepwise production system includes five chromatography columns, which are loaded sequentially according to the process flow and conventional operating procedures. The solutions to be chromatographically analyzed (first solution, second solution, cation exchange solution, third solution, and hydrophobic solution) are obtained by filtration using a standard 0.22μm filter cartridge. Using a stepwise production system, production can be completed in 2–6 days.

[0053] If a faster production process is required, a continuous production system (continuous flow production design) can be used. See [link to relevant documentation]. Figure 2 and Figure 3 A continuous production system is designed based on a stepwise production system. During the processing of the first, second, cation-phase, third, and hydrophobic solutions, no protein precipitation occurs (achieved through precise pH and conductivity control via online addition of equilibration / diluent between columns), which is one of the fundamental principles enabling a continuous production system.

[0054] like Figure 2 As shown, the plasma albumin preparation equipment of this technical solution includes a computer 9 and a chromatography unit chassis 10. The chromatography unit chassis 10 includes a chassis shell, one side of which is a fixing surface 11 for fixing chromatography columns and other accessories, and another side of which is a grille 12 for assisting heat dissipation of the internal units. Various units and storage tanks (for storing various buffer solutions and intermediate products) are fixed inside the chassis shell. The above settings are conventional settings for chromatography equipment and are all existing technologies, which will not be described in detail here. The main improvement of this technical solution is that, in order to achieve rapid separation and purification of plasma albumin, the connection method and sequence of the chromatography columns have been set. That is, the main improvement lies in the chromatography unit of the plasma albumin preparation equipment fixed on the fixing surface 11 of the chassis shell of the chromatography unit 10.

[0055] like Figure 3As shown, the chromatography unit includes a first anion exchange chromatography column 1, a second anion exchange chromatography column 2, a cation exchange chromatography column 3, a third anion exchange chromatography column 4, and a hydrophobic chromatography column 5, which are connected in sequence by pipelines. Figure 3 Solid lines represent the main material flow pipelines, solid arrows indicate the flow direction, and dashed lines indicate the waste liquid flow direction. In this technical solution, the chromatography column, pipelines, and storage containers are all disposable equipment to ensure that there are no sources of contamination, viruses, bacteria, etc. in the intermediate process. The material flows continuously in the pipeline without stopping, realizing continuous production. The chromatography column, pipelines, pump 7, valve 8, etc. in this technical solution are all conventional components or equipment used in existing technologies for chromatography analysis or production.

[0056] The sample inlet of the first anion exchange chromatography column 1 is connected to a first tubing 13 and a second tubing 14. Both the first and second tubings are equipped with pumps 7 and valves 8 along the direction of material flow. The first tubing 13 is used to transport the supernatant after plasma centrifugation (the preparation method is detailed in step (1) of section (I) above). The second tubing 14 is used to transport the equilibration solution and diluent, which are used to adjust the pH and conductivity of the liquid, respectively. The equilibration solution and diluent can be buffers such as phosphate buffer or citrate buffer. By adding appropriate equilibration and diluent to the material, the pH and conductivity of the chromatographic solution in each step can be ensured to be within the set range. The amount of each and the solute concentration can be calculated through calculation and routine experiments. The equilibration solution and diluent are transported to the second tubing 14 through their respective branch lines. The supernatant after plasma centrifugation completes pH and conductivity adjustment (by mixing the equilibration and diluent) to form the first chromatographic solution, which then enters the first anion exchange chromatography column 1. The sample outlet of the first anion exchange chromatography column 1 is connected to the second anion exchange chromatography column 2 via a third conduit 15, which is connected to a fourth conduit 16. The first chromatographic solution flows through the first anion exchange chromatography column 1, forming the first chromatographic flow solution, which flows through the third conduit 15 to the second anion exchange chromatography column 2. The fourth conduit 16 is used to discharge waste liquid or collect samples (for detecting intermediate process samples). The third conduit 15 is sequentially equipped with a valve 8, a pump 7, and another valve 8, while the fourth conduit 16 is equipped with a valve 8.

[0057] The sample inlet of the second anion exchange chromatography column 2 is connected to the third pipeline 15 and also to the fifth pipeline 17. A pump 7 and a valve 8 are installed on the fifth pipeline 17 along the direction of material flow. The third pipeline 15 is used to transport the first chromatography flow-through solution, and the fifth pipeline 17 is used to transport the equilibration solution and diluent. The first chromatography flow-through solution undergoes pH and conductivity regulation to form the second chromatography solution, which enters the second anion exchange chromatography column 2. The sample outlet of the second anion exchange chromatography column 2 is connected to the cation exchange chromatography column 3 via the sixth pipeline 18, which is also connected to the seventh pipeline 19. The second chromatography solution flows through the second anion exchange chromatography column 2, forming the second chromatography flow-through solution, which flows through the sixth pipeline 18 to the cation exchange chromatography column 3. The seventh pipeline 19 is used to discharge waste liquid or collect samples (for detecting intermediate process samples). The sixth pipeline 18 is sequentially equipped with valve 8, pump 7, and valve 8, and the seventh pipeline 19 is equipped with valve 8.

[0058] The sample inlet of the cation exchange chromatography column 3 is connected to both the sixth tubing 18 and the eighth tubing 20. A pump 7 and a valve 8 are installed on the eighth tubing 20 along the material flow direction. The sixth tubing 18 is used to deliver the second chromatography flow-through solution, while the eighth tubing 20 is used to deliver the equilibration solution, diluent, and eluent. The second chromatography flow-through solution undergoes pH and conductivity regulation to form the cation exchange chromatography solution, which then enters the cation exchange chromatography column 3. The sample outlet of the cation exchange chromatography column 3 is connected to the third anion exchange chromatography column 4 via the ninth tubing 21. The ninth tubing 21 is also connected to the tenth tubing 22, which is used to discharge waste liquid or collect samples (for intermediate process sample detection). The cation exchange chromatography solution flows through the cation exchange chromatography column 3, forming the cation chromatography flow-through solution, which then flows into the third anion exchange chromatography column 4 through the ninth tubing 21. The ninth tubing 21 is sequentially equipped with valve 8, pump 7, and valve 8, while the tenth tubing 22 is equipped with valve 8.

[0059] The sample inlet of the third anion exchange chromatography column 4 is connected to both the ninth tubing 21 and the eleventh tubing 23. Pumps 7 and valves 8 are installed on the eleventh tubing 23 along the direction of material flow. The ninth tubing 21 is used to deliver the cation exchange chromatography flow-through solution, and the eleventh tubing 23 is used to deliver the equilibration solution and diluent. The cation exchange chromatography flow-through solution undergoes pH and conductivity regulation to form the third chromatographic solution, which enters the third anion exchange chromatography column 4. The sample outlet of the third anion exchange chromatography column 4 is connected to the hydrophobic chromatography column 5 via the twelfth tubing 24, which is also connected to the thirteenth tubing 25. The third chromatographic solution flows through the third anion exchange chromatography column 4, forming the third chromatographic flow-through solution, which flows through the twelfth tubing 24 to the hydrophobic chromatography column 5. The thirteenth tubing 25 is used to discharge waste liquid or collect samples (for intermediate process sample detection). The twelfth pipeline 24 is equipped with valve 8, pump 7 and valve 8 in sequence, and the thirteenth pipeline 25 is equipped with valve 8.

[0060] The sample inlet of the hydrophobic chromatography column 5 is connected to both the twelfth tubing 24 and the fourteenth tubing 26. A pump 7 and a valve 8 are installed on the fourteenth tubing 26 along the direction of material flow. The twelfth tubing 24 is used to deliver the third chromatography flow-through solution, and the fourteenth tubing 26 is used to deliver the equilibration solution and diluent. The third chromatography flow-through solution undergoes pH and conductivity regulation to form the hydrophobic chromatography solution, which then enters the hydrophobic chromatography column 5. The sample outlet of the hydrophobic chromatography column 5 is connected to downstream equipment (which can be a collection device or directly connected to a sterilization device) via the fifteenth tubing 27. The fifteenth tubing 27 is also connected to the sixteenth tubing 28, which is used to discharge waste liquid or collect samples (for testing intermediate process samples). A valve 8 is installed on the sixteenth tubing 28. The hydrophobic chromatography solution flows through the hydrophobic chromatography column 5 and flows into the downstream equipment from the fifteenth tubing 27.

[0061] The flow rate is controlled by the pumping speed of pump 7 and the opening percentage of valve 8 in pipelines 13, 14, 15, 17, 18, 20, 21, 23, 24, and 26. For example, the flow rate ratio can be controlled as 5:1:1:2:1:1:1:2:1:1. Under the process conditions of this technical solution, the above flow rate ratio can ensure that the pH and conductivity of the five chromatography solutions are within the required range (see "(I)" for the required range). The parameters can be preset according to conventional methods of the prior art to ensure the above flow rate, and the concentration and amount of equilibrium liquid and diluent can be determined according to conventional methods in the art, so real-time monitoring is not required. A computer 9 can be used to automatically detect and monitor pH, conductivity and perform UV monitoring. Since the flow rate and other parameters have been preset, this technical solution may not require the installation of pH and conductivity monitoring equipment.

[0062] The equipment in this technical solution can process 1 to 10 plasma samples. The five chromatography columns have the following specifications: 10–100 mm (diameter) × 20–30 cm (length). The product (hydrophobic chromatography flow-through solution) prepared by this solution is in solution form and can be directly processed for subsequent sterilization and dispensing without the need for separate preparation, thus saving operating costs. In addition, the preparation time using this technical solution is very short; a single plasma sample can be purified within 3–6 hours.

[0063] Example 2 This embodiment is basically the same as embodiment 1, except that in the preparation process of plasma albumin preparation, in "(1) Raw material plasma treatment", a cold precipitation separation unit is used to separate the material to be loaded onto the column, which is consistent with the cold precipitation separation unit in the prior patents, namely: "CN116236820A A continuous production system for single-person plasma IgG products" and "CN116574175A A single-person plasma IgG product and its preparation method".

[0064] like Figure 4 As shown, in terms of equipment, this embodiment adds a cold precipitation separation unit 6 at the start of the continuous production system in Embodiment 1. For the specific structure of the cold precipitation separation unit 6, please refer to... Figure 5 and Figure 6 The cryoprecipitation separation unit 6 includes a refrigeration component and a plasma separation kit. In this embodiment, the refrigeration component specifically uses a cold box 37. The plasma separation kit includes a first container 29 and a second container 35. The first container 29 is snapped onto the second container 35 and they are sealed to each other. The bottom of the first container 29 is open, and a filter membrane 33 with a pore size of 0.22 μm is sealed at the opening using conventional methods. A top cover 30 is provided on the top of the first container 29, and a stirring assembly 31 is installed in the top cover 30. The stirring assembly 31 includes a rotating shaft and a stirring paddle. The rotating shaft passes through the top cover 30 and is fixed to the output shaft of a motor 32 by screws. The motor 32 is fixed to the top cover 30 by screws. A pressure regulating pipe 34 is connected to the second container 35, and an outlet pipe 36 is connected to the bottom of the second container 35. The outlet pipe 36 is used to connect to the first pipeline 13. The plasma separation kit can be placed entirely in the cold box 37, or it can be placed as follows: Figure 6 As shown, only the first container 29 is placed in the cold box 37, which is fixed to the frame using conventional methods. When using this device, fresh plasma is first poured into the first container 29 under sterile conditions, the top cover 30 is placed on top, and after cooling to 0-2°C, the motor 32 is started to stir the plasma. Simultaneously, the pressure inside the second container 35 is adjusted to negative pressure through the pressure regulating pipe 34. After the fresh plasma is filtered, the filtrate enters the second container 35. After filtration, the filtrate is transported to subsequent processes through the outlet pipe 36, as detailed in Example 1.

[0065] To ensure that the filtered plasma can smoothly and fully enter subsequent processes, the plasma separation kit can be configured as follows: Figure 7The second container 35 is open at the bottom and sealed with a pressurized filter membrane 38. A third container 39 is snapped into the bottom of the second container 35 and they are sealed together. The third container 39 is inverted conical in shape and its bottom is connected to the outlet pipe 36. When using this device, after filtration, the second container 35 is pressurized through the pressure regulating pipe 34, and all the filtrate is transferred to the third container 39. Because the third container 39 is inverted conical in shape, it can be ensured that all the filtrate enters the outlet pipe 36. For details of the subsequent process, please refer to Example 1.

[0066] Example 3 The following explanation uses a single-dose plasma albumin product as an example, with the raw plasma specifically being plasma from healthy individuals. The effectiveness of this equipment and process is illustrated using healthy human plasma as an example. The standard plasma collection specification is 600g / 580ml per bag per person, meaning each bag of raw plasma constitutes one unit, and each unit contains 600g / 580ml of plasma. The equipment in this scheme (either a stepwise or continuous production system) can process 1 to 10 units of raw plasma. The five-step chromatography operation, including the selected packing materials, chromatography column specifications, processing methods, and parameters of the samples to be chromatographically analyzed, is shown in Table 1. To study the process effect of each step, the following experiments did not use a continuous flow production system but instead employed a five-step chromatography stepwise approach (using a stepwise production system).

[0067] Table 1: Process Parameter Settings

[0068] To study the albumin preparation effect, the operation steps and parameter settings for enriching and purifying albumin from healthy human plasma using the system of this technical solution are as follows (unless otherwise specified, the following methods and parameter settings will be used in subsequent experiments): (1) Take a sample of raw plasma, disinfect the surface with 75% ethanol, break the plasma bag, control the temperature at 3℃ to melt, and centrifuge the plasma at a speed of 10000rpm / min or higher and collect the supernatant.

[0069] (2) First Anion Exchange Chromatography: Adjust the pH of the supernatant of the centrifuged plasma to 7.6 (selectable range 6.8–7.7) and the conductivity to 12.0 mS / cm (selectable range 10.0–12.0 mS / cm). Filter the supernatant using a 0.22 μm filter cartridge to obtain the first chromatography solution. Perform the first anion exchange chromatography on the first chromatography solution to adsorb IgM and coagulation factors. Collect the flow-through containing albumin (first chromatography flow-through) for the next chromatography step. In specific operation, the chromatography column used for the first anion exchange chromatography is 26 mm × 25 cm, and the packing material is Fractogel EMD TMAE(M) (Merck). After packing the chromatography column with the packing material, equilibrate the column using sodium citrate-sodium chloride buffer (pH 7.6; 5~20mM sodium citrate, 0.07~0.12M sodium chloride; preferably 15mM sodium citrate, 0.10M sodium chloride). The initial loading volume of the first chromatographic solution is 10mL of the first chromatographic solution / mL of packing material. The above operation is only one specific implementation method. In actual operation, other column specifications and strong anion exchange packing materials can be selected according to the process yield requirements. The column equilibration method can be determined according to the specific packing material selected, and the loading volume is also determined according to the properties of the packing material and the sample conditions, which will not be elaborated further below.

[0070] (3) Second anion exchange chromatography: Adjust the conductivity of the first chromatography flow-through to 6.0 mS / cm (selectable range 4.0–9.0 mS / cm) and the pH to 6.5 (selectable range 6.0–7.2). After filtration with a 0.22 μm filter cartridge, obtain the second chromatography solution. Perform a second anion exchange chromatography on the second chromatography solution to remove trace amounts of impurities and proteins. Collect the flow-through containing albumin (second chromatography flow-through) for the next chromatography step. The selection of the second anion exchange chromatography column and packing material, as well as the loading volume of the second chromatography solution, are the same as in step (2).

[0071] (4) Cation exchange chromatography: Adjust the pH of the second cation exchange buffer to 5.4 (selectable range 5.2-5.4) and the conductivity to 2.0 mS / cm (selectable range 0.5-2.0 mS / cm). Filter with a 0.22 μm filter cartridge to obtain the cation exchange chromatography solution. Load the cation exchange chromatography solution onto the cation exchange chromatography column and collect the flow-through to obtain the cation exchange chromatography flow-through. In specific operation, the chromatography column used for the first cation exchange chromatography is 26 mm × 25 cm, and the packing material is Unigel 80sp (Suzhou Nanomicro). After packing the chromatography column with the packing material, equilibrate the chromatography column with citrate-phosphate buffer (pH 5.4; 0.025-0.05 M disodium hydrogen phosphate, citrate is used to adjust pH; preferably: 0.015 M disodium hydrogen phosphate). The loading volume of the cation exchange chromatography solution is 25 mL of the third cation exchange chromatography solution / mL packing material.

[0072] (5) Third anion exchange chromatography: Adjust the conductivity of the flow-through buffer from the previous cation exchange chromatography to 1.5 mS / cm (selectable range 1.5–2.5 mS / cm) and the pH to 7.6 (selectable range 6.5–7.6). Filter the buffer using a 0.22 μm filter cartridge to obtain the third chromatography buffer. Load the third chromatography buffer onto the anion exchange chromatography column to remove trace amounts of impurities and collect the flow-through buffer to obtain the third chromatography flow-through buffer. In specific operation, the chromatography column used for the third anion exchange chromatography is 16 mm × 25 cm, and the packing material is trimethyl quaternary ammonium strong anion packing material (GPQ-60, Suzhou Bojin, can be used). After packing the chromatography column with the packing material, equilibrate the chromatography column with tromethamine-hydrochloric acid buffer (pH 7.6, conductivity 1.5 mS / cm; 0.01–0.03 M tromethamine, pH adjusted with hydrochloric acid; preferably 0.02 M tromethamine). The loading amount of the third chromatography solution is 180g of the total protein content in the third chromatography solution per L of packing material.

[0073] (6) Hydrophobic chromatography: Adjust the pH of the third chromatography flow-through after filtration to 7.6 (selectable range 7.4-7.6) and the conductivity to 40 mS / cm (selectable range 12-82 mS / cm) to obtain the hydrophobic chromatography solution. Load the hydrophobic chromatography solution onto the hydrophobic chromatography column and collect the flow-through. In specific operations, the chromatography column used for hydrophobic chromatography is 26 mm × 20 cm, and the packing material is Diamond Butyl (butyl-type weakly hydrophobic interaction chromatography). After packing the chromatography column with the packing material, equilibrate the chromatography column with tromethamine-hydrochloric acid-sodium chloride buffer (pH 7.6, conductivity 40 mS / cm; 0.015~0.03 M tromethamine, adjust pH with hydrochloric acid, adjust conductivity with sodium chloride; preferably 0.02 M tromethamine). The loading amount of the hydrophobic chromatography solution is 550 g of total protein in the hydrophobic chromatography solution / L packing material.

[0074] Subsequent operations were carried out in accordance with Example 1, and subsequent experimental studies were conducted using the above-described operating method.

[0075] Experimental Example 1 This experimental example tested the conditions of the sample to be chromatographically analyzed in five steps. Unless otherwise specified, the operation method is the same as the optimal method in Example 3. Other parameter adjustments are shown in Tables 2-6. After adjusting the pH and conductivity values, the albumin yield (calculated based on the total amount of albumin in the material before sample loading and the flow-through liquid in this step, representing the single-step yield) and purity were analyzed. The experimental results are shown in Tables 2-6.

[0076] Table 2: Experimental conditions and results of the first anion exchange chromatography experiment (values ​​are the average of three independent experiments).

[0077] As shown in Table 2, the experimental data indicates that precise requirements are placed on the conductivity and pH of the first chromatography solvent during the first anion exchange chromatography step to efficiently separate albumin from plasma. A high albumin yield can be obtained by controlling the pH at 6.8–7.7 and the conductivity at 10.0–12.0 mS / cm. This method differs from the method in the prior patent (CN116574175A). The prior patent requires the purification of IgG from plasma, thus necessitating adjustments to the conductivity and pH of the first chromatography solvent to 9.0–15.0 mS / cm and 6.8–7.7, respectively, resulting in a wider range of conductivity and pH values. In contrast, this technical solution is specifically designed for albumin in plasma, allowing for a narrower suitable pH and conductivity range. In particular, in this protocol, adjusting the conductivity from slightly below 10.0 mS / cm to 9.0 mS / cm reduces the yield from >90% to 86%; similarly, adjusting the conductivity from slightly above 13.0 mS / cm to 9.0 mS / cm reduces the yield from 99% to 88%. However, this phenomenon does not occur with IgG. This indicates that the albumin enrichment and purification process in this protocol has specific requirements for the pH and conductivity of the pre-chromatographic material. Preferably, the conductivity needs to be controlled at 12.0 mS / cm and the pH at 7.7.

[0078] Table 3: Experimental conditions and results of the second anion exchange chromatography experiment (values ​​are the average of three independent experiments).

[0079] As shown in Table 3, the pH value of the second chromatography solution needs to be controlled between 6.0 and 7.2 (preferably 6.0), and the conductivity needs to be controlled between 4.0 and 9.0 (preferably 5.0) to ensure a high albumin yield.

[0080] Table 4: Experimental conditions and results of cation exchange chromatography (values ​​are the average of three independent experiments)

[0081] As shown in Table 4, the sample pH and conductivity have a significant impact on the yield and purity of albumin in the cation exchange chromatography step, and there are strict requirements for both.

[0082] Under optimal conditions (Experiments 12–14), when the sample pH is controlled at 5.2–5.4 and the conductivity is maintained at 2.0 mS / cm, the yield of albumin in the flow-through solution can reach 93%–97%, and the purity can be stably maintained above 92.6%, achieving a good balance between yield and purity.

[0083] In stark contrast, when the pH value shifted only slightly (Comparative Experiment 4: pH 5.45; Comparative Experiment 5: pH 5.5), even with the conductivity remaining constant, the albumin purity decreased significantly, dropping to 88.8% and 86.8% respectively, a decrease of 4–6 percentage points. Similarly, when the pH was maintained at its optimal value of 5.4, adjusting the conductivity to 1.5 mS / cm (Comparative Experiment 6) or 2.5 mS / cm (Comparative Experiment 7) also resulted in a sharp drop in albumin purity to 80.5% and 83.6% respectively, with the yield also being severely compromised (the yield in Comparative Experiment 6 was only 86%).

[0084] The above comparative results clearly demonstrate that in this chromatographic system, pH and conductivity are not independent, loose parameters, but rather exhibit an extremely narrow synergistic effect. According to conventional knowledge in the art, chromatographic operations typically have a wide operational flexibility, and the influence of each parameter often shows a linear, gradual trend. However, this discovery shows that under the critical conditions of pH 5.2–5.4 and conductivity 2.0 mS / cm, albumin purity and yield simultaneously reach excellent levels far exceeding those in adjacent ranges. Once deviating from this range (e.g., a pH increase of only 0.05 or a conductivity shift of only 0.5 mS / cm), both indicators experience a precipitous deterioration. This nonlinear mutation of performance leap within the critical window and sharp decline outside the window is something that those skilled in the art could not reasonably anticipate through conventional process optimization or linear extrapolation. The unpredictability of its technical effect fully demonstrates the inventiveness of this invention in the cation exchange chromatography separation of IgG and albumin step (with a focus on purifying and enriching albumin).

[0085] Table 5: Experimental conditions and results of the third anion exchange chromatography experiment (values ​​are the average of three independent experiments).

[0086] Table 6: Experimental conditions and results of hydrophobic chromatography (values ​​are the average of three independent experiments)

[0087] The above descriptions are merely embodiments of the present invention, and common knowledge such as specific technical solutions and / or characteristics are not described in detail here. It should be noted that those skilled in the art can make various modifications and improvements without departing from the technical solutions of the present invention, and these should also be considered within the scope of protection of the present invention. These modifications and improvements will not affect the effectiveness of the implementation of the present invention or the practicality of the patent. The scope of protection claimed in this application should be determined by the content of its claims, and the specific embodiments described in the specification can be used to interpret the content of the claims.

Claims

1. A method for the preparation of a single serving of a plasma albumin preparation, characterized in that: Centrifuge or filter the plasma and collect the liquid phase. The liquid phase was subjected to a first anion exchange chromatography, a second anion exchange chromatography, a cation exchange chromatography, a third anion exchange chromatography, and a hydrophobic chromatography in sequence to obtain the plasma albumin product.

2. A process for the preparation of a single serving plasma albumin product according to claim 1, characterized by: In the first anion exchange chromatography, the pH of the liquid phase was adjusted to 6.8–7.7 and the conductivity to 10.0–12.0 mS / cm to obtain the first chromatography solution; The first chromatographic solution is loaded into an anion exchange chromatography column, and the flow-through is collected to obtain the first chromatographic flow-through.

3. A process for the preparation of a single serving plasma albumin preparation according to claim 2, characterized in that: In the second anion exchange chromatography, the pH of the first chromatography flow-through solution was adjusted to 6.0–7.2 and the conductivity to 4.0–9.0 mS / cm to obtain the second chromatography solution. The second chromatographic solution is loaded into an anion exchange chromatography column, and the flow-through is collected to obtain the second chromatographic flow-through.

4. A process for the preparation of a single serving plasma albumin preparation according to claim 3, characterized in that: In cation exchange chromatography, the pH of the second chromatography flow-through solution is adjusted to 5.2–5.4 and the conductivity to 0.5–2.0 mS / cm to obtain the cation exchange chromatography solution. The cation exchange chromatography solution is then loaded onto the cation exchange chromatography column, and the flow-through solution is collected to obtain the cation exchange chromatography flow-through solution.

5. A process for the preparation of a single serving plasma albumin preparation according to claim 4, characterized by: After the third anion exchange chromatography, the pH of the cation exchange chromatography flow-through was adjusted to 6.5–7.6 and the conductivity to 1.5–2.5 mS / cm to obtain the third chromatography solution. The third chromatography solution was then loaded into the anion exchange chromatography column, and the flow-through was collected to obtain the third chromatography flow-through.

6. The method for preparing a single-dose plasma albumin product according to claim 5, characterized in that: In hydrophobic exchange chromatography, the pH of the third chromatography flow-through solution is adjusted to 7.4–7.6 and the conductivity to 12–82 mS / cm to obtain the hydrophobic chromatography solution. The hydrophobic chromatography solution is then loaded onto the hydrophobic chromatography column, and the flow-through solution is collected to obtain the hydrophobic chromatography flow-through solution.

7. The method for preparing a single-dose plasma albumin product according to claim 6, characterized in that: After ultrafiltration, dialysis and concentration, the hydrophobic chromatography flow-through solution is mixed with sodium octanoate and sodium chloride to obtain an intermediate product with a protein content >100 g / L, a sodium octanoate content of 0.120-0.200 mmol / g protein, a sodium chloride content of 50-150 mmol / L, and a pH value of 6.2-7.

6. After pasteurization and filtration, the intermediate products are used to obtain albumin products.

8. A process for the preparation of a single serving plasma albumin preparation according to claim 7, characterized by: The ligand of the packing material used in cation exchange chromatography is sulfopropyl; the ligand of the packing material used in hydrophobic chromatography is butyl or phenyl.

9. A process for the preparation of a single serving plasma albumin preparation according to claim 8, characterized by: The packing material used for the first and second anion exchange chromatography was trimethylaminoethyl; the packing material used for the third anion exchange chromatography was trimethylquaternary ammonium.

10. The plasma albumin product prepared by the method for preparing a single-dose plasma albumin product according to any one of claims 1-9.

Citation Information

Patent Citations

  • Continuous production system for single-person plasma IgG products

    CN116236820A

  • Single plasma IgG product and preparation method thereof

    CN116574175A